| Press Release | Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations | Teva Pharmaceutical | 0 | 10 months 2 weeks ago |
| Press Release | Teva Announces Donations of Essential Medicines in Support of Ukrainian Refugees | Teva Pharmaceutical | 0 | 3 years 2 weeks ago |
| Press Release | New Phase 3 Data Presented at Psych Congress 2021 Showed TV-46000/mdc-IRM Significantly Prolonged Time to Impending Relapse Compared to Placebo in Patients with Schizophrenia | Teva Pharmaceutical | 0 | 3 years 2 months ago |
| Press Release | Teva Statement Following New York Jury Ruling in Opioids Trial | Teva Pharmaceutical | 0 | 3 years 2 months ago |
| Press Release | Teva Announces Launch of $4,000,000,000 Offering of Sustainability-linked Senior Notes | Teva Pharmaceutical | 0 | 3 years 5 months ago |
| Press Release | Showcasing Tevas Commitment to Helping Patients Have More Migraine-Free Days, 18 Abstracts will be presented, Including One Late-Breaker, on AJOVY (fremanezumab-vfrm) Injection at the International Headache Society and European Headache... | Teva Pharmaceutical | 0 | 3 years 7 months ago |
| Press Release | Teva Announces Changes to Executive Management Team | Teva Pharmaceutical | 0 | 3 years 8 months ago |
| Press Release | Teva Announces Virtual 2020 Annual Meeting of Shareholders | Teva Pharmaceutical | 0 | 4 years 7 months ago |
| Press Release | China Approves AUSTEDO For Treating Chorea Associated with Huntington's Disease and Tardive Dyskinesia in Adults | Teva Pharmaceutical | 0 | 4 years 10 months ago |
| Press Release | Teva to Present New Data on AJOVY (fremanezumab-vfrm) Injection at the American Headache Societys 61st | Teva Pharmaceutical | 0 | 4 years 10 months ago |
| Press Release | Teva and Celltrion Healthcare Announce the Launch of TRUXIMA (rituximab-abbs) Injection for Rheumatoid Arthritis, the Only Biosimilar to Rituxan (rituximab) Available in the United States for This Indication | Teva Pharmaceutical | 0 | 4 years 10 months ago |
| Press Release | New Data For Teva AJOVY (fremanezumab-vfrm) Injection and AUSTEDO (deutetrabenazine) Tablets Included in Neurology | Teva Pharmaceutical | 0 | 4 years 11 months ago |
| Press Release | Findings describe the efficacy and safety results of clinical trials of fremanezumab through 12 months of treatment in patients with chronic and episodic migraine | Teva Pharmaceutical | 0 | 4 years 11 months ago |
| Press Release | Teva Announces U.S. Launch of Autoinjector for AJOVY (fremanezumab-vfrm) Injection | Teva Pharmaceutical | 0 | 4 years 11 months ago |
| Press Release | Teva Pharmaceutical Industries Ltd. | Teva Pharmaceutical | 0 | 4 years 11 months ago |
| Press Release | Teva to Donate Potential COVID-19 Treatment, Hydroxychloroquine Sulfate Tablets to Hospitals Nationwide | Teva Pharmaceutical | 0 | 5 years 1 week ago |
| Press Release | Teva and Celltrion Healthcare Announce U.S. Availability of HERZUMA (trastuzumab-pkrb) for Injection | Teva Pharmaceutical | 0 | 5 years 1 week ago |
| Press Release | Avis favorable de l'Institut national pour l'excellence clinique (NICE) pour le premier traitement anti-PRGC de la migraine : AJOVY (fremanezumab) | Teva Pharmaceutical | 0 | 5 years 2 weeks ago |
| Press Release | Positive Empfehlung des NICE fur die erste, gegen das CGRP gerichtete Migranetherapie: AJOVY (Fremanezumab) | Teva Pharmaceutical | 0 | 5 years 2 weeks ago |
| Press Release | Positive Recommendation by NICE for first anti-CGRP migraine therapy: AJOVY (fremanezumab) | Teva Pharmaceutical | 0 | 5 years 2 weeks ago |
| Press Release | Teva Announces FDA Approval of ArmonAir Digihaler (fluticasone propionate) Inhalation Powder | Teva Pharmaceutical | 0 | 5 years 1 month ago |
| Press Release | Teva Announces Registration Trials of Deutetrabenazine in Pediatric Patients with Tourette Syndrome Did Not Meet the Primary Endpoint | Teva Pharmaceutical | 0 | 5 years 1 month ago |
| Press Release | New Report Shows Teva Generic Medicines Saved US Healthcare System $41.9 Billion | Teva Pharmaceutical | 0 | 5 years 1 month ago |
| Press Release | Teva to Present at the 38th Annual J.P. Morgan Healthcare Conference | Teva Pharmaceutical | 0 | 5 years 2 months ago |
| Press Release | Pictured right to left: Dr. Hafrun Fridriksdottir, Executive Vice President, Teva R&D; Prof. Daniel Zajfman, President of the Weizmann Institute of Science. (Photo credit: Eyal Tuag) | Teva Pharmaceutical | 0 | 5 years 3 months ago |
